Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lx-2931 SCHEMBL304963 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL304964 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL20744226 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL316870 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL306099 | 0.99 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL306100 | 0.99 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL4382659 | 0.99 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| SCHEMBL316038 | 0.87 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL10069449 | 0.87 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL316037 | 0.87 | L3MBTL1 (0.30) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | AC BIOSCIENCE (CH) | 2023-12-26 | — | — | US | claimed |
| EP-3668506-B1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2023-12-06 | — | — | EP | claimed |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | claimed |
| EP-3668506-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BioScience (CH) | 2020-06-24 | — | — | EP | claimed |
| WO-2019034768-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2019-02-21 | — | — | WO | claimed |
| EP-4017844-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | AC BIOSCIENCE (CH) | 2023-12-26 | — | — | US | disclosed |
| EP-3668506-B1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-20220306587-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2022-09-29 | — | — | US | disclosed |
| CN-114555567-A | Compounds and their use for the treatment of infectious diseases and cancer | AC生命科学有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | disclosed |
| EP-3668506-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BioScience (CH) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034768-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | SPHK1, S1PR1, S1PR2 | L3MBTL1 3874/4885CYP1A2 4495/4885 |
| US-20220306587-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | SGPL1, SPHK1, S1PR1 | L3MBTL1 256/4885CYP1A2 2539/4885 |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | SPHK1, S1PR1, S1PR2 | L3MBTL1 3874/4885CYP1A2 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.